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Purpose: We evaluated the incidence and risk factors of postoperative nausea and 
vomiting (PONV) in patients with fentanyl-based intravenous patient-controlled 
analgesia (IV-PCA) and single antiemetic prophylaxis of 5-hydroxytryptamine 
type 3 (5 HT3)-receptor antagonist after the general anesthesia. Materials and 
Methods: In this retrospective study, incidence and risk factors for PONV were 
evaluated with fentanyl IV-PCA during postoperative 48 hours after various sur-
geries. Results: Four hundred-forty patients (23%) of 1878 had showed PONV. 
PCA was discontinued temporarily in 268 patients (14%), mostly due to PONV 
(88% of 268 patients). In multivariate analysis, female, non-smoker, history of 
motion sickness or PONV, long duration of anesthesia (>180 min), use of desflu-
rane and intraoperative remifentanil infusion were independent risk factors for 
PONV. If one, two, three, four, five, or six of these risk factors were present, the 
incidences of PONV were 18%, 19%, 22%, 31%, 42%, or 50%. Laparoscopic sur-
gery and higher dose of fentanyl were not risk factors for PONV. Conclusion: De-
spite antiemetic prophylaxis with 5 HT3-receptor antagonist, 23% of patients with 
fentanyl-based IV-PCA after general anesthesia showed PONV. Long duration of 
anesthesia and use of desflurane were identified as risk factors, in addition to risk 
factors of Apfel’s score (female, non-smoker, history of motion sickness or 
PONV). Also, intraoperative remifentanil infusion was risk factor independent of 
postoperative opioid use. As the incidence of PONV was up to 50% according to 
the number of risk factors, risk-adapted, multimodal or combination therapy 
should be applied.
Key Words:   Analgesia, antiemetics, fentanyl, patient-controlled, postoperative 
nausea and vomiting
INTRODUCTION
Postoperative nausea and vomiting (PONV) is one of the most common complica-
tions after general anesthesia, occurring up to 80%.1 Although PONV is often self-
limiting, it has been cited by patients as more uncomfortable than postoperative 
pain.2
Original Article http://dx.doi.org/10.3349/ymj.2014.55.5.1430pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 55(5):1430-1435, 2014
Postoperative Nausea and Vomiting
Yonsei Med J   http://www.eymj.org   Volume 55   Number 5   September 2014 1431
(diabetes, hypertension, radiation therapy and chemothera-
py). Anesthesia- and operation-related variables were the 
duration of anesthesia, use of volatile anesthetics and intra-
operative remifentanil infusion, emergency, laparoscopy, 
and operation site. Postoperative variables were PCA-related 
complications (headache, dizziness, sedation, pruritis, and 
hypotension), verbal numerical rating scale (VNRS, 0--10, 
0=no symptoms; 10=worst) for pain, incidence of nausea, 
retching or vomiting, and requirement of rescue analgesic 
or antiemetic. PCA-related variables included total dose of 
fentanyl for two days (μg/kg), use of combined ketorolac in 
PCA, and discontinuation of PCA. In routine practice, PONV 
and pain intensity were recorded by a nurse in charge of PCA 
management at six times during postoperative 48 hrs (in 
post-anesthesia care unit, postoperative 1--6, 6--12, 12--18, 
18--24, 24--48 hrs). Failure of pain management was defined 
as greater than 4 of VNRS score.
Statistical analysis 
Values are expressed as mean±SD or the number of pa-
tients (%), as appropriate. Logistic regression models were 
used to identify univariate and multivariate predictors for 
PONV. Univariate logistic regression analysis was used 
first to identify possible risk factors for PONV, and the mul-
tivariate model included variables that were significant on 
univariate analysis. For all analyses, a p-value <0.05 was 
considered statistically significant. SAS 9.1 software (SAS 
Institute, Inc., Cary, NC, USA) was used to analyze the data.
RESULTS
 
A total of 1878 adults were included after the exclusion of 
161 patients (46; incomplete data, 94; sedation due to me-
chanical ventilation, 21; reoperation within 48 hours after 
surgery). Table 1 shows patients’ characteristics. Of 1878 
adults, 1654 patients (89%) were maintained with volatile 
anesthetics. Nitrous oxide was not used in all cases. In most 
cases (96%), remifentanil was infused intraoperatively. 
Fentanyl 16±3 ug/kg (mean±SD, range 8--29 µg/kg) was 
diluted in 100 mL with saline for 48 hrs PCA infusion. Fen-
tanyl was administered at basal rate 1--2 mL/hr with bolus 
0.5--1.0 mL and lock-out time 15--20 min. In most cases 
(93%), 4 mg of ondansetron was administered intravenous-
ly before the end of surgery and 16 mg mixed in PCA was 
infused during postoperative 48 hrs for the antiemetic pro-
phylaxis. Single bolus of ramosetron (1%), granisetron 
Perioperative opioid use has been known to be an inde-
pendent risk factor for PONV. While an opioid-free pain 
management after surgery is ideal in terms of reducing 
PONV, opioids play a critical role in routine postoperative 
analgesic therapy. As the laparoscopic surgery with less 
pain is becoming popular, intravenous opioid use for post-
operative analgesia is an alternative to invasive regional an-
algesia. Considering that most patients undergoing surgery 
have one or two risk factors and 20--40% of these patients 
are predicted to suffer from PONV,1,3 effective prophylaxis 
for PONV should be considered in patients with postopera-
tive opioid use.
The 5-hydroxytryptamine type 3 (5 HT3) receptor antago-
nist is the mainstay of antiemetic therapy, even though there 
are still controversies whether risk-adapted strategy is better 
than liberal approach.4-6 In our institution, single drug therapy 
of 5 HT3-receptor antagonist has been administered intrave-
nously before the end of surgery in patients with fentanyl-
based intravenous patient-controlled analgesia (IV-PCA) af-
ter general anesthesia without risk assessment for PONV. 
However, whether single drug prophylaxis for PONV is 
enough especially in high risk patients, needs a reassessment.
Therefore, in this retrospective study, we evaluated the in-
cidence and the risk factors of PONV in patients with fen-
tanyl-based IV-PCA and single antiemetic prophylaxis with 
5 HT3-receptor antagonist after the general anesthesia.
MATERIALS AND METHODS
After Institutional Review Board approval (approval no: 3- 
2011-0238) and registration on clinicaltrials.gov (NCT0152 
7890), we reviewed electronic medical records of 2039 
adults with fentanyl-based IV-PCA after general anesthesia 
at a university hospital between May to October in 2011. 
The need for informed consent was waived for this study. 
Patients undergoing various surgeries were included in this 
study while patients undergoing outpatient operation were 
excluded. If multiple operations were performed within two 
days after first operation, the patients were excluded. 
Single antiemetic prophylaxis with 5 HT3-receptor antag-
onist was done in all patients after the surgery.
Demographic and perioperative variables known to possi-
bly be related to PONV were noted. Demographic variables 
included age; sex; body mass index; American Society of 
Anesthesiologists (ASA) physical status; history of smok-
ing, motion sickness or PONV; previous medical history 
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Table 2 shows the results of univariate analysis of risk fac-
tors for PONV. Laparoscopic surgery and dose of fentanyl 
were not associated with PONV. Sevoflurane decreased the 
incidence of PONV in comparison to desflurane, although 
use of volatile anesthetics increased the incidence of PONV 
(Table 2). Also, total intravenous anesthesia with propofol 
was not associated with PONV. Failure of postoperative 
pain management (defined as VNRS >4) was not associat-
ed with PONV. In the multivariate analysis, female sex, 
non-smoker, previous history of motion sickness or PONV, 
longer anesthesia than 180 min (from data mining), use of 
desflurane and intraoperative remifentanil infusion were 
identified as independent risk factors for PONV (Table 3). 
Table 4 shows the incidence of PONV according to the risk 
score based on six risk factors from our results.
DISCUSSION
In this retrospective study, the incidence of PONV in patients 
with fentanyl-based IV-PCA after general anesthesia was 
23% despite single drug prophylaxis of 5 HT3-receptor an-
tagonist. PCA was discontinued temporarily in 14% of total 
patients, mostly due to PONV. Female, non-smoker, history 
of motion sickness or PONV, longer anesthesia than 180 
min, use of desflurane, and intraoperative infusion of remi-
fentanil were risk factors for PONV. Postoperative pain man-
agement with opioid is associated with increasing PONV.1,3,7 
The incidence of PONV has been reported to be 20--40% in 
patients with postoperative opioids.8-11 However, the inci-
dence can approximate 80% in patients with multiple risk 
factors for PONV, if antiemetic prophylaxis is not appropri-
ate.12,13 Compared to the incidence (34% and 45%) of pre-
vious studies used same regimen for PCA and prophylactic 
antiemetic,8,9 ours was slightly lower (23%), probably due 
to heterogeneous study cohort and antiemetic was infusion 
in most cases (93%) during 48 hours. However, the rate of 
PCA discontinuation (14%) in our study was similar to that 
in Song, et al.8 (10%).
Our study confirmed that female, non-smoker, history of 
motion sickness or PONV were independent risk factors for 
PONV, previously known as the components of Apfel’s risk 
score.1,14 Also, our result demonstrated that intraoperative 
remifentanil infusion was a separate risk factor [odds ratio 
(OR) 2.82] in patients with postoperative fentanyl in PCA 
regimen. Volatile anesthetic increased PONV (OR 1.47, 
p=0.04) in accordance with other studies.7 Interestingly, 
(0.1%), palonosetron (3%), or ondansetron (2%) was used 
in other cases. Four hundred-forty patients (23%) of 1878 
had showed PONV during postoperative 48 hr (Table 1). 
Incidence of PONV according to time after surgery was il-
lustrated in Fig. 1. PCA was discontinued temporarily in 
268 patients (14%), mostly due to PONV (88% of 268 pa-
tients). 
Table 1. Patient, Anesthetic and Operative Characteristics, 
and Postoperative Conditions 
Variables n=1878
Patient characteristics
    Age (yrs)   51±18
    Female (%)    964 (51)
    BMI (kg/m2) 23.7±3.6
    Smoker (%)    393 (21)
Anesthetic condition 
    Duration of anesthesia (min)   246±196
    Volatile anesthetics (%) 1654 (89)
       Desflurane   797 (43)
       Sevoflurane   859 (46)
    Intraoperative remifentanil infusion (%) 1796 (96)
Emergency (%)  166 (9)
Laparoscopy (%)    295 (16)
Postoperative complications (%) 
    Nausea, retching or vomiting   440 (23)
    Headache   41 (2)
    Dizziness 151 (8)
    Sedation        4 (0.2)
    Pruritis        9 (0.5)
    Hypotension        7 (0.4)
Discontinuation of PCA   268 (14)
Requirement of rescue antiemetic 
  including routine order (%) 
1165 (62)
BMI, body mass index; PCA, patient controlled analgesia.
Results are presented as the mean±SD or number of patients (percentage).
Fig. 1. Incidence of postoperative nausea and vomiting (PONV) during the 
first 48 h after surgery.
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though propofol is generally assumed to be antiemetic. 
Some reports have demonstrated that propofol with opioid 
did not reduce the incidence of PONV compared to bal-
anced anesthesia with opioid.16-19 Longer duration of anes-
thesia was identified as a risk factor for PONV, similar to 
desflurane increased PONV compared to sevoflurane (OR 
1.42). Meta-analysis by Macario, et al.15 that showed no 
difference in PONV frequency between desflurane and 
sevoflurane. Total intravenous anesthesia with propofol and 
remifentanil did not reduce the incidence of PONV, al-
Table 2. Univariate Analysis of Risk Factors for Postoperative Nausea and Vomiting (PONV) 
Variables Odds ratio 95% CI p value
Demographic data 
    Age 1.00 0.99--1.00   0.19
    Female 3.15 2.50--3.98 <0.0001
    BMI <25 0.64 0.51--0.79   0.0008
    Non-smoker 2.72 1.96--3.78 <0.0001
    Low ASA class 0.64 0.51--0.79 <0.0001
    Motion sickness 2.80 2.11--3.72 <0.0001
    Previous PONV 3.19 1.66--6.13   0.0005
Operative characteristics
    Emergency 0.55 0.36--0.86   0.01
    Laparoscopy 1.00 0.74--1.34   0.99
Anesthetic condition
    Duration of anesthesia  1.54 1.24--1.91 <0.0001
    Volatile anesthetics 1.47 1.02--2.10   0.04
    Sevoflurane 0.78 0.63--0.97   0.03
    Desflurane (vs. sevoflurane) 1.42 1.13--1.78   0.002
    TIVA with propofol 0.79 0.53--1.19   0.26
    Intraoperative opioid infusion 2.56 1.27--5.16   0.01
PCA details
    Dose of fentanyl 1.01 0.97--1.04   0.71
    Use of ketorolac 1.03 0.58--1.82   0.93
Complications
    Failure of pain control (VNRS >4) 1.32 0.92--1.91   0.13
    Routine prescription of rescue analgesics 1.50 1.11--2.02   0.01
    Rescue analgesics 1.27 1.01--1.61   0.04
    Headache 5.35   2.83--10.12 <0.0001
    Dizziness 0.47 0.28--0.79   0.004
    Sedation 1.26 1.03--1.54   0.03
    Pruritis 0.94 0.19--4.51   0.93
    Hypotension 0.55 0.07--4.53   0.57
BMI, body mass index; TIVA, total intravenous anesthesia; PCA, patient controlled analgesia; VNRS, verbal numerical rating scale; CI, confidence interval; 
ASA, American Society of Anesthesiologists.
Table 3. Multivariate Analysis of Risk Factors for Postoperative Nausea and Vomiting (PONV) 
Variables Odds ratio 95% CI p value
Female 2.30 1.76--3.01 <0.0001
Non-obese (BMI <25) 0.96 0.75--1.23   0.73
Non-smoker 1.59 1.10--2.30   0.01
Motion sickness or previous PONV 1.89 1.39--2.56 <0.0001
Duration of anesthesia (>180 min) 1.48 1.17--1.86   0.0009
Use of desflurane 1.52 1.21--1.92   0.0004
Use of intraoperative remifentanil infusion 2.82 1.36--5.86   0.006
High dose of fentanyl in PCA (20 µg kg-1) 1.02 0.69--1.50   0.94
BMI, body mass index; PCA, patient controlled analgesia; CI, confidence interval.
Jong Bum Choi, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 5   September 20141434
emetics.29 However, recent studies suggest that compliance 
with these algorithms may be poor and that high-risk pa-
tients often do not receive appropriate antiemetic prophy-
laxis; thus, rather than risk-adapted approach, liberal and 
fixed combination prophylaxis could be advantageous for a 
larger proportion of patients.5 As the risk reduction by pre-
ventive interventions is proportion to baseline risk,30 the 
prophylaxis may be less advantageous in low-risk patients. 
The preventive intervention titration including the multiple 
uses of antiemetic and the avoidance of emetogenic anes-
thetics is appropriate and should be based on the simplified 
and validated risk-scoring system.
This retrospective study had some limitations. The nurse 
in charge of evaluating the efficacy and safety of PCA did 
not visit six times during each time period. The patients 
were asked to rate their worst nausea during each time peri-
od. This might result in bias in recalling events and an un-
der-estimation of the incidence of PONV. Another limita-
tion is recall bias that is originated from ignoring less severe 
PONV as absent.
In conclusion, PONV incidence is still 23% despite of 
single antiemetic prophylaxis in patient with fentanyl-based 
IV-PCA after general anesthesia. Combination therapy or 
multimodal approach should be considered. We identified 
female gender, non-smoker, history of motion sickness or 
PONV, long duration of anesthesia (>180 min), use of des-
flurane, and intraoperative infusion of remifentanil as risk 
factors for PONV in our population. We recommend that as-
sessing for the six risk factors identified in this study would 
add value to the risk assessment of PONV.
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